How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

226 results for

Uterotonic Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Use of Antihypertensive Medications and Uterotonics During Delivery Hospitalizations in Women With Asthma. (PubMed)

Use of Antihypertensive Medications and Uterotonics During Delivery Hospitalizations in Women With Asthma. To estimate whether the diagnosis of asthma is associated with the use of specific uterotonic and antihypertensive medications during delivery hospitalizations.We used Perspective, an administrative database, to determine whether women hospitalized for delivery complicated by postpartum hemorrhage or preeclampsia received uterotonics and antihypertensive medications differentially based (...) on the absence or presence of asthma from 2006 to 2015. Given that carboprost and intravenous (IV) labetalol may be associated with asthma exacerbation, adjusted models for receipt of these medications were created with adjusted risk ratios with 95% CIs as measures of effect. Risk for status asthmaticus based on receipt of carboprost and IV labetalol was analyzed.Over the study period, a total of 5,691,178 women were analyzed, of whom 239,915 (4.2%) had preeclampsia and 139,841 postpartum hemorrhage (2.5

2018 Obstetrics and Gynecology

2. Uterotonic Medication

Uterotonic Medication Uterotonic Medication Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Uterotonic Medication Uterotonic (...) Medication Aka: Uterotonic Medication , Oxytocics II. Indications III. Preparations ( ) Onset in 3 to 5 minutes Intramuscular: 10-20 units Intravenous: 40 units/liter at 250 cc/hour (Methergine) Dosing: 0.2 mg IM or PO every 6-8 hours Onset in 2 to 5 minutes Contraindications Hypersensitivity Prostaglandin (Hemabate) Dosing: 0.25mg Intramuscular or Intra-Myometrium Onset <5 minutes Administer every 15 minutes to maximum of 2 mg 600 mcg PO or PR Images: Related links to external sites (from Bing

2018 FP Notebook

3. Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial

Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03584854 Recruitment Status : Not yet recruiting First Posted : July 12, 2018 Last Update Posted

2018 Clinical Trials

4. Postpartum Uterotonic Administration

Postpartum Uterotonic Administration Postpartum Uterotonic Administration - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Postpartum Uterotonic Administration The safety and scientific validity (...) Suleyman Training and Research Hospital Information provided by (Responsible Party): Eser Sefik Ozyurek, Bagcilar Training and Research Hospital Study Details Study Description Go to Brief Summary: The investigators are planning to determine the effect of the timing of oxytocin administration on the amount of blood loss, necessity for additional medical or surgical interventions. Condition or disease Intervention/treatment Phase Postpartum Bleeding Drug: Oxytocin Not Applicable Detailed Description

2015 Clinical Trials

5. Uterotonic Prophylaxis Trial

: Placebo Placebo group Drug: Placebo Outcome Measures Go to Primary Outcome Measures : Excessive bleeding [ Time Frame: Approximately 1-2 hours after procedure ] Clinical factors included in composite outcome of excessive bleeding after D&E Post-procedure total blood loss > 125cc (after D&E) Transfusion Admission for bleeding Re-aspiration for bleeding Balloon tamponade Uterine artery embolization Major surgery for bleeding At least 1 uterotonic medication given Prescription given for any uterotonic (...) Uterotonic Prophylaxis Trial Uterotonic Prophylaxis Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Uterotonic Prophylaxis Trial (UPT) The safety and scientific validity of this study

2015 Clinical Trials

6. Uterotonic Medication

Uterotonic Medication Uterotonic Medication Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Uterotonic Medication Uterotonic (...) Medication Aka: Uterotonic Medication , Oxytocics II. Indications III. Preparations ( ) Onset in 3 to 5 minutes Intramuscular: 10-20 units Intravenous: 40 units/liter at 250 cc/hour (Methergine) Dosing: 0.2 mg IM or PO every 6-8 hours Onset in 2 to 5 minutes Contraindications Hypersensitivity Prostaglandin (Hemabate) Dosing: 0.25mg Intramuscular or Intra-Myometrium Onset <5 minutes Administer every 15 minutes to maximum of 2 mg 600 mcg PO or PR Images: Related links to external sites (from Bing

2015 FP Notebook

7. Can Cooling the Uterus During Cesarean Section Decrease Blood Loss, Decrease Uterotonic Drug Use, and Decrease the Number of Emergency Hysterectomies?

uterotonic medications, and fewer hysterectomies following cesarean section. The investigators suspect that it may. Condition or disease Intervention/treatment Phase Postpartum Hemorrhage Uterine Atony Procedure: Uterine Cooling Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 200 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Prevention Official (...) : Change in Pre- vs Post-operative Hematocrit [ Time Frame: 48 hours post operative period ] Use of Uterotonic Medications [ Time Frame: During surgery and in the PACU (approximately 3 total hours) ] Use of Extra Oxytocin [ Time Frame: Intraoperatively ] Use of Methergine [ Time Frame: Intraoperatively ] Use of Hemabate [ Time Frame: Intraoperatively ] Use of Cytotec [ Time Frame: Intraoperatively ] Bakri Bulb Placement [ Time Frame: Intraoperatively ] Use of Additional Measures to Control Blood Loss

2014 Clinical Trials

8. Reply: Uterotonic agents should be avoided during cesarean hysterectomy for placenta previa accreta until evidence is forthcoming. (PubMed)

Reply: Uterotonic agents should be avoided during cesarean hysterectomy for placenta previa accreta until evidence is forthcoming. 23889350 2013 12 03 2018 12 02 1600-0412 92 11 2013 Nov Acta obstetricia et gynecologica Scandinavica Acta Obstet Gynecol Scand Reply to Ngene et al. (2013): Uterotonic agents should be avoided during cesarean hysterectomy for placenta previa accreta until evidence is forthcoming. 1339 10.1111/aogs.12227 Matsubara Shigeki S Department of Obstetrics and Gynecology (...) , Jichi Medical University, Shimotsuke, Tochigi, Japan. eng Letter Comment United States Acta Obstet Gynecol Scand 0370343 0001-6349 IM Acta Obstet Gynecol Scand. 2013 Apr;92(4):372-7 23323568 Acta Obstet Gynecol Scand. 2013 Nov;92(11):1338 23869593 Cesarean Section methods Female Humans Hysterectomy methods Placenta Accreta epidemiology surgery Placenta Previa epidemiology surgery Pregnancy 2013 7 30 6 0 2013 7 31 6 0 2013 12 16 6 0 ppublish 23889350 10.1111/aogs.12227

2013 Acta Obstetricia et Gynecologica Scandinavica

9. Oxytocin And Uterotonic Agent Use For Cesarean Delivery

Oxytocin And Uterotonic Agent Use For Cesarean Delivery Oxytocin And Uterotonic Agent Use For Cesarean Delivery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Oxytocin And Uterotonic Agent Use For Cesarean (...) , Brigham and Women's Hospital Study Details Study Description Go to Brief Summary: The central objective of this study will be to evaluate a standardized, evidence-based regimen versus a conventional regimen for uterotonic drug dosing for elective cesarean delivery The investigators primary hypothesis is that the proposed uterotonic drug regimen, when compared to conventional dosing regimen, during elective cesarean delivery will: 1. Reduce the overall amount of oxytocin and other uterotonic agents

2012 Clinical Trials

10. Interruption of nonviable pregnancies of 24?28 weeks' gestation using medical methods

of uterotonics (e.g., misoprostol) and fetal expulsion. Although time is typicallyanonparametricassessment,weincorporated data from studies that also reported means. ? Outcome success: Studies varied in their definition of success, from complete expulsion by the intended medical regimen (e.g., without the need for surgical intervention) to a specific time frame, most often 24 or 48 h. We chose to focus on the most commonly used definition, expulsion of the fetus by the intended medical regimen, though we (...) . Median time to expulsion after the first misoprostol dose was 6.4 h in the laminaria group and 9.0 h in the no-laminaria group (p=.01). Another study found no decreaseintimetoexpulsionwhenlaminariawereaddedtoa misoprostol-only regimen [14]. Is there any role for additional uterotonics after misoprostol administration? Successfulexpulsionwasoftenaccomplishedwithoutthe need for adjunctive medications [6,7,9,15,17]. However, the use of additional agents was difficult to interpret, since reasons for use

2013 Society of Family Planning

11. First-trimester abortion in women with medical conditions

and misoprostol are acceptable uterotonic agents for such patients [19]. The U.S. Medical Eligibility Criteria for Contraceptive Use provide guidelines for contraceptive choice in hypertensive women seeking postabortion contra- ception [6]. Obesity Surgicalabortionforobesewomenmaybeassociatedwith increased technical difficulty [35] and, for second-trimester procedures, with adverse outcomes such as increased blood loss [35,36]; prompt care is therefore important. Ventilation difficulties with deep sedation (...) First-trimester abortion in women with medical conditions Clinical Guidelines First-trimester abortion in women with medical conditions Release date October 2012 SFP Guideline #20122 Abstract Most women undergoing first-trimester abortion are healthy. However, abortion providers also encounter women with a wide variety of medical conditions, some of which are serious and complex. When such a condition exists, consultation with the woman's physician or a specialist can facilitate decision making

2012 Society of Family Planning

12. Does Mednav, a Medical Navigation System, Aid Non-technical and Technical Skills in the Simulated Obstetric Emergency?

Does Mednav, a Medical Navigation System, Aid Non-technical and Technical Skills in the Simulated Obstetric Emergency? Does Mednav, a Medical Navigation System, Aid Non-technical and Technical Skills in the Simulated Obstetric Emergency? - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Does Mednav, a Medical Navigation System, Aid Non-technical and Technical Skills in the Simulated Obstetric Emergency? The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02783131 Recruitment Status : Completed First

2016 Clinical Trials

13. Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage

Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02686840 Recruitment Status : Completed First Posted : February 22, 2016 Last Update Posted : August 16, 2017

2016 Clinical Trials

14. Retained Placenta: will medical treatment ever be possible? (PubMed)

Retained Placenta: will medical treatment ever be possible? The standard treatment for retained placenta is manual removal whatever its subtype (adherens, trapped or partial accreta). Although medical treatment should reduce the risk of anesthetic and surgical complications, they have not been found to be effective. This may be due to the contrasting uterotonic needs of the different underlying pathologies. In placenta adherens, oxytocics have been used to contract the retro-placental (...) myometrium. However, if injected locally through the umbilical vein, they bypass the myometrium and perfuse directly into the venous system. Intravenous injection is an alternative but exacerbates a trapped placenta. Conversely, for trapped placentas, a relaxant could help by resolving cervical constriction, but would worsen the situation for placenta adherens. This confusion over medical treatment will continue unless we can find a way to diagnose the underlying pathology. This will allow us to stop

Full Text available with Trip Pro

2016 Acta Obstetricia et Gynecologica Scandinavica

15. Screening, Diagnosis, and Management of Placenta Accreta Spectrum Disorders

of the guideline committee were selected on the basis of their ongoing expertise in managing this condition across Canada and by practice setting. The committee reviewed all available evidence in the English medical literature, including published guidelines, and evaluated diagnostic tests, surgical procedures, and clinical outcomes. Evidence Published literature, including clinical practice guidelines, was retrieved through searches of Medline and The Cochrane Library to March 2018 using appropriate (...) evidence to recommend giving or withholding uterotonic drugs after delivery of the fetus (III-C). 10 Presently there is insufficient evidence to recommend either approach (preoperative balloon placement or intraoperative ligation) designed to arrest blood flow from the internal iliac arteries prior to hysterectomy (II-1C). 11 Focal central disease may be amenable to wedge resection, with complete removal of the placenta and repair of the uterus (the triple-P procedure) (II-3B). 12 Classical Caesarean

2019 Society of Obstetricians and Gynaecologists of Canada

16. Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage

to all women (I-A). 2 Oxytocin (10 IU), administered intramuscularly, is the preferred medication and route for the prevention of PPH in low-risk vaginal deliveries. Care providers should administer this medication after delivery of the anterior shoulder (I-A). 3 Intravenous infusion of oxytocin (20 to 40 IU in 1000 mL, 150 mL per hour) is an acceptable alternative for AMTSL (I-B). 4 An IV bolus of oxytocin, 5 to 10 IU (given over 1 to 2 minutes), can be used for PPH prevention after vaginal birth (...) and to decrease the need for therapeutic uterotonics. (I-B) 7 For women delivering vaginally with 1 risk factor for PPH, carbetocin 100 µg IM decreases the need for uterine massage to prevent PPH when compared with continuous infusion of oxytocin (I-B). 8 Ergonovine, 0.2 mg IM, and misoprostol, 600 to 800 µg given by the oral, sublingual, or rectal route, may be offered as alternatives in vaginal deliveries when oxytocin is not available (II-1B). 9 Whenever possible, delaying cord clamping by at least 60

2018 Society of Obstetricians and Gynaecologists of Canada

17. Primary postpartum haemorrhage

when determining optimal route) · Repeated doses not recommended Prescribing considerations · Not LAM approved as first line medication 41 · Increases pyrexia greater than 38 O C (misoprostol versus controls RR 3.97, 95% CI 3.13 to 5.04) 60 o Greater than 40 O C reported in 1–14% 61 Evidence summary · No strong evidence that misoprostol is more effective than other uterotonics 60,62,63 · Most useful where injectable uterotonics are unavailable 52 or contraindicated (e.g. asthma, hypertension (...) and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect. The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate

2019 Queensland Health

18. Concise practice guidance on the prevention and management of accidental awareness during general anaesthesia

) rapidly attaining adequate end-tidal volatile levels after induction without delay (c) use of nitrous oxide in appropriate concentrations (d) appropriate use of short-acting opiates (e) after induction, avoid reducing concentration of inhalational anaesthetic agents as a means to preserve or improve uterine tone, as this increases the risk of AAGA and instead use appropriate uterotonic drugs and physical haemostatic measures Maintenance Transfer to theatre/patient positioning: ‘mind the gap (...) . AAGBI: Consent for anaesthesia 2017. Anaesthesia 2017; 72: 93–105. 12. General Medical Council. Consent: Patients and Doctors Making Decisions Together. GMC: London, July 2008. 13. AAGBI. Pre-operative Assessment and Patient Information. AAGBI: London, January 2010. 14. Pandit JJ, Carey A. Estimating the duration of common elective operations: implications for operating list management. Anaesthesia 2006: 61: 768–76. 15. Pandit JJ. Similarity of operation times for common general surgical procedures

2019 Association of Anaesthetists of GB and Ireland

19. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights

Grading of Recommendations Assessment, Development and Evaluation GRC Guidelines Review Committee GVPS Global Values and Preferences Survey HIVST HIV self-testing HPV human papillomavirus HPVSS HPV self-sampling HRP The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction IPCHS Integrated People-Centred Health Services framework MEC Medical eligibility criteria for contraceptive use (WHO publication) OCP oral contraceptive pill OPK (...) the following working definition of self-care: Self-care is the ability of individuals, families and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health- care provider. The scope of self-care as described in this definition includes health promotion; disease prevention and control; self-medication; providing care to dependent persons; seeking hospital/specialist/primary care if necessary; and rehabilitation, including

2019 World Health Organisation Guidelines

20. WHO recommendations: intrapartum care for a positive childbirth experience

, and to have a sense of personal achievement and control through involvement in decision-making, even when medical interventions are needed or wanted. This up-to-date, comprehensive and consolidated guideline on essential intrapartum care brings together new and existing World Health Organization (WHO) recommendations that, when delivered as a package, will ensure good-quality and evidence-based care irrespective of the setting or level of health care. The recommendations presented in this guideline (...) services, health care professionals (including nurses, midwives, general medical practitioners and obstetricians) and academic staff involved in training health care professionals. Guideline development methods Throughout this guideline, the term “healthy pregnant women” is used to describe pregnant women and adolescent girls who have no identified risk factors for themselves or their babies, and who otherwise appear healthy. The guideline was developed using standard operating procedures in accordance

2018 World Health Organisation Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>